CROSS chemoradiation
Checked 2026-09-09
Resectable oesophageal or junctional cancer (T1N1 or T2-3N0-1), before surgery
One cycle
weekly × 5 · about 5 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Carboplatin Cytotoxic chemotherapy (platinum) | AUC 2 | IV | D1 | |
Paclitaxel Cytotoxic chemotherapy (taxane) | 50 mg/m² | IV | D1 | |
Radiotherapy | 1.8 Gy per fraction, 5 days a week | Radiotherapy | D1-5 |
Cycles
5 weekly doses with 41.4 Gy in 23 fractions
7-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine
Notes
- CheckMate 577: adjuvant nivolumab for one year if residual disease at surgery.
Used in
Trials
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
mFOLFOX6
Adjuvant stage III colon (6 months) or metastatic colorectal and upper GI first line
every 14 days × 12
CAPOX
Adjuvant stage III colon (3 or 6 months), rectal total neoadjuvant therapy, metastatic first line
every 21 days × 4
FOLFIRI
Metastatic colorectal first or second line (with bevacizumab, aflibercept, ramucirumab or an anti-EGFR antibody)
every 14 days
FLOT
Resectable gastric or gastro-oesophageal junction adenocarcinoma, cT2 or higher or node-positive
every 14 days × 4
Nivolumab + FOLFOX or CAPOX
Unresectable or metastatic HER2-negative gastric, junctional or oesophageal adenocarcinoma, first line (benefit concentrated in PD-L1 CPS 5 or above)
every 14 days
Pembrolizumab + cisplatin + fluorouracil
Advanced oesophageal or Siewert type 1 junctional cancer, first line
every 21 days